- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07855146
Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique (AVAPAM)
Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique : a Before-and-after Study
This is a prospective, single-centre, quasi-experimental before-and-after study. Women due to give birth at the participating centre will be informed about the study during their 9th-month antenatal appointment. Only expectant mothers for whom cervical ripening is indicated will be included. During the BEFORE period, cervical ripening will be offered to them according to the method chosen by the healthcare team following a discussion of their case at a team meeting. During the AFTER period, the various possible methods of cervical ripening will be offered to the patient, and the choice of method will be left to her.
The participants' experiences will be compared using the QEVA self-assessment questionnaire, completed two days after delivery.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Induction of labour is a common practice in France, and the rate is rising. Cervical ripening and induction of labour are often associated with negative maternal experiences of labour and childbirth. The experience of childbirth has a significant influence on the early mother-child relationship, as well as on the relationship between the parents. A negative experience of childbirth is a major risk factor for postnatal depression and post-traumatic stress disorder.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mélanie JUNKE
- Telefonnummer: 0033387179886
- E-post: projet-recherche-clinique@chr-metz-thionville.fr
Studiesteder
-
-
-
Peltre, Frankrike, 57245
- CHR METZ-THIONVILLE, Hôpital Femme Mère Enfant
-
Ta kontakt med:
- Mélanie JUNKE
- Telefonnummer: 0033387179886
- E-post: projet-recherche-clinique@chr-metz-thionville.fr
-
Hovedetterforsker:
- Dr Cristina-Elena DOROFTE, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Female patients aged over 18
- Patients who gave their written consent after receiving information to enable them to make an informed decision about the study
- Patients with a medical or non-medical indication for induction of labour who are admitted to the maternity ward of the participating centre
Exclusion Criteria:
- Patients with a history of uterine scarring (a history of uterine scarring is a contraindication to prostaglandins)
- Patients requiring urgent maturation
- Patients requiring induction of labour in connection with a medical termination of pregnancy or foetal death in utero
- Patients who are unable to complete the questionnaire (due to a lack of proficiency in the language, cognitive impairments, etc.)
- Women deprived of their liberty and/or protected by law
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Period before
|
Cervical ripening will be offered to them in accordance with the approach chosen by the healthcare team following a discussion of her case at a team meeting. |
|
Eksperimentell: Period after
|
Choice of cervical ripening technique from the following: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta®, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Score of the first dimension of the QEVA questionnaire
Tidsramme: 2 days after giving birth
|
Total score of the dimension: 'emotions during childbirth' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Evaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Score of the second dimension of the QEVA questionnaire
Tidsramme: 2 days after giving birth
|
Total score of the dimension 'interactions with healthcare professionals' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the third dimension of the QEVA questionnaire
Tidsramme: 2 days after giving birth
|
Total score of the dimension 'first moments with the baby' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 3 to 12, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the fourth dimension of the QEVA questionnaire
Tidsramme: 2 days after giving birth
|
Total score of the dimension : 'feeling during the postpartum period' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 4 to 16, a higher score means a worse outcome. |
2 days after giving birth
|
|
Procedures for informing patients about their experience of childbirth
Tidsramme: 2 days after giving birth
|
Multiple choice: 1/information provided by a healthcare professional during a consultation (the patient's referring obstetrician or midwife), 2/our hospital's patient information leaflet, 3/antenatal classes, and 4/other sources (social media, etc.), expressed as percentages of the total number of participants. |
2 days after giving birth
|
|
Impact of the duration of antenatal care on the experience of childbirth
Tidsramme: At baseline
|
Assessment of the duration of care from the start of maturation to birth (days) |
At baseline
|
|
Impact of the maturation technique used on the experience of childbirth
Tidsramme: At baseline
|
Assessment of the impact of the ripening technique used on the childbirth experience for the following techniques: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon) |
At baseline
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Cristina-Elena DOROFTE, MD, CHR Metz Thionville Hopital Femme Mère Enfant
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-02-CHRMT
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .